Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database.
Cancer risk
Lynch syndrome
MLH1
MSH2
MSH6
Mortality
PMS2
Prospective study
Survival
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
12
10
2022
revised:
19
01
2023
accepted:
27
02
2023
pubmed:
14
5
2023
medline:
14
5
2023
entrez:
14
5
2023
Statut:
epublish
Résumé
The Prospective Lynch Syndrome Database (PLSD) collates information on carriers of pathogenic or likely pathogenic MMR variants ( The PLSD is a prospective observational study without a control group that was designed in 2012 and updated up to October 2022. Data for 8500 carriers of Gynaecological cancers were more frequent than colorectal cancers in In We acknowledge funding from the Norwegian Cancer Society, contract 194751-2017.
Sections du résumé
Background
UNASSIGNED
The Prospective Lynch Syndrome Database (PLSD) collates information on carriers of pathogenic or likely pathogenic MMR variants (
Methods
UNASSIGNED
The PLSD is a prospective observational study without a control group that was designed in 2012 and updated up to October 2022. Data for 8500 carriers of
Findings
UNASSIGNED
Gynaecological cancers were more frequent than colorectal cancers in
Interpretation
UNASSIGNED
In
Funding
UNASSIGNED
We acknowledge funding from the Norwegian Cancer Society, contract 194751-2017.
Identifiants
pubmed: 37181409
doi: 10.1016/j.eclinm.2023.101909
pii: S2589-5370(23)00086-X
pmc: PMC10166779
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101909Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
R.B. has received honoraria for lectures and advisory boards from AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Illumina, Lilly, Merck-Serono, MSD, Novartis, Qiagen, Pfizer, Roche, and Targos MP Inc. R.B. is a Co-Founder and Scientific Advisor for Targos Mol. Pathology Inc. Kassel/Germany. T.T.S. is the CEO and co-owner of Healthfund Finland Oy and reports consultation fees from Boehringer Ingelheim Finland and Amgen. FB is supported by JANSSEN PHARMACEUTICALS (clinical trial for Familial Adenomatous polyposis). RH is supported by the 10.13039/501100002424Fujifilm Germany and Janssen-Pharmaceuticals. LK is consultant of Sandoz, Novartis and Abbott. GM reports consultancy fees from Johnson & Johnson.